Brief: Moonlake Immunotherapeutic to Present Phase 2 Mira Primary Analysis Trial Results With Nanobody® Sonelokimab In Hidradenitis Suppurativa At The European Academy Of Dermatology And Venereology Congress

MoonLake Immunotherapeutics

04/10/2023 12:20

Oct 4 (Reuters) - MoonLake Immunotherapeutics  MLTX.O :
    * PHASE 2 MIRA PRIMARY ANALYSIS TRIAL RESULTS (12-WEEK) FOR
MOONLAKE’S NANOBODY® SONELOKIMAB IN HIDRADENITIS SUPPURATIVA TO
BE PRESENTED AT A LATE-BREAKING SESSION AT THE EUROPEAN ACADEMY
OF DERMATOLOGY AND VENEREOLOGY CONGRESS
    * MOONLAKE IMMUNOTHERAPEUTICS - TOP-LINE 12-WEEK RESULTS FOR
MOONLAKE'S PHASE 2 ARGO TRIAL WITH NANOBODY SONELOKIMAB IN PSA
EXPECTED IN H1 OF NOV 2023
    * MOONLAKE IMMUNOTHERAPEUTICS - 24-WEEK PHASE 2 MIRA TRIAL
DATA
FOR NANOBODY(®) SONELOKIMAB IN HIDRADENITIS SUPPURATIVA IS
ANTICIPATED IMMINENTLY

Source text for Eikon:  ID:nGNX8nDDrZ 
Further company coverage:  MLTX.O 

 ((Reuters.Briefs@thomsonreuters.com))